vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Has Consensus Target Price of $55.83

vTv Therapeutics Inc. (NASDAQ:VTVT) has been assigned an average rating of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $55.83.

A number of brokerages recently issued reports on VTVT. Wall Street Zen raised vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Lifesci Capital upgraded vTv Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 2nd. Zacks Research upgraded vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. BTIG Research reaffirmed a “buy” rating and set a $57.00 price objective on shares of vTv Therapeutics in a research note on Wednesday, October 14th. Finally, HC Wainwright decreased their price objective on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, August 6th.

vTv Therapeutics Stock Performance

VTVT opened at $21.03 on Friday. vTv Therapeutics has a one year low of $20.56 and a one year high of $44.00. The company has a market cap of $82.86 million, a P/E ratio of -22.86 and a beta of 0.28. The business’s 50-day simple moving average is $29.22 and its 200-day simple moving average is $33.23.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.15. As a group, analysts predict that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On vTv Therapeutics

A hedge fund recently raised its stake in vTv Therapeutics stock. China Universal Asset Management Co. Ltd. raised its position in vTv Therapeutics Inc. (NASDAQ:VTVT) by 114.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 5,360 shares of the biotechnology company’s stock after acquiring an additional 2,860 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in vTv Therapeutics were worth $161,000 at the end of the most recent reporting period. Institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.